1998 issue 4


Volume 14, issue 4


Inhibitory metylotransferazy katecholowej (COMT) w leczeniu choroby Parkinsona

Włodzimierz Kuran1
1. I Klinika Neurologiczna Instytutu Psychiatrii i Neurologii w Warszawie
Farmakoterapia w Psychiatrii i Neurologii, 1998, 4, 71-78


This paper presents essential patobiochemical objectives and clinical problems and results concerning the treatment of parkinsonian patients with two COMT inhibitors: entacapone and tolcapone. In November 1998, due to increased hepatotoxicity, tolcapone was withdrawn from the market.